Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 16/20 | 0.86 |
| ▸ | FBP1 | P09467 | 3/20 | 0.86 |
| ▸ | ERBB2 | P04626 | 4/20 | 0.63 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.63 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.63 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.63 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.63 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.63 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.63 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.63 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.63 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.63 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.63 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.63 |
| ▸ | ILK | Q13418 | 2/20 | 0.61 |
| ▸ | KDR | P35968 | 4/20 | 0.60 |
| ▸ | CLK1 | P49759 | 2/20 | 0.60 |
| ▸ | RET | P07949 | 2/20 | 0.60 |
| ▸ | KIF5B | P33176 | 2/20 | 0.60 |
| ▸ | AURKA | O14965 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1507616 | 0.92 | EGFR (1.00) | EGFRFBP1ERBB2HDAC3HDAC4 | |
| Hydrochloric Acid SCHEMBL1507764 | 0.91 | EGFR (0.98) | EGFRFBP1ERBB2HDAC3HDAC4 | |
| SCHEMBL643039 | 0.88 | EGFR (0.84) | EGFRFBP1ERBB2HDAC3HDAC4 | |
| SCHEMBL14964660 | 0.84 | EGFR (0.83) | EGFRFBP1ERBB2HDAC3HDAC4 | |
| SCHEMBL644023 | 0.84 | EGFR (0.83) | EGFRFBP1ERBB2HDAC3HDAC4 | |
| SCHEMBL1657530 | 0.84 | EGFR (0.80) | EGFRFBP1ERBB2HDAC3HDAC4 | |
| SCHEMBL8213640 | 0.84 | EGFR (0.85) | EGFRFBP1ERBB2KDRCLK1 | |
| SCHEMBL2615523 | 0.83 | EGFR (0.80) | EGFRFBP1ERBB2HDAC3HDAC4 | |
| SCHEMBL1507449 | 0.83 | EGFR (0.80) | EGFRFBP1ERBB2HDAC3HDAC4 | |
| Hydrochloric Acid SCHEMBL1507642 | 0.82 | EGFR (0.78) | EGFRFBP1ERBB2HDAC3HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9181277-B2 | Aminoquinazoline derivatives and their salts and methods of use | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2015-11-10 | — | — | US | disclosed |
| US-20150284340-A1 | QUINAZOLINE BASED EGFR INHIBITORS CONTAINING A ZINC BINDING MOIETY | CURIS INC (US) | 2015-10-08 | — | — | US | disclosed |
| US-20150274678-A1 | QUINAZOLINE BASED EGFR INHIBITORS CONTAINING A ZINC BINDING MOIETY | CURIS INC (US) | 2015-10-01 | — | — | US | disclosed |
| US-9108929-B2 | Quinazoline based EGFR inhibitors | CURIS, INC. (US) | 2015-08-18 | — | — | US | disclosed |
| US-9024024-B2 | Quinazoline based EGFR inhibitors containing a zinc binding moiety | CURIS, INC. (US) | 2015-05-05 | — | — | US | disclosed |
| US-8975401-B2 | Quinazoline based EGFR inhibitors containing a zinc binding moiety | CURIS, INC. (US) | 2015-03-10 | — | — | US | disclosed |
| US-8846912-B2 | Tartrate salts of quinazoline based EGFR inhibitors containing a zinc binding moiety | CURIS, INC. (US) | 2014-09-30 | — | — | US | disclosed |
| US-20140228361-A1 | AMINOQUINAZOLINE DERIVATIVES AND THEIR SALTS AND METHODS OF USE | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2014-08-14 | — | — | US | disclosed |
| US-20140221403-A1 | QUINAZOLINE BASED EGFR INHIBITORS CONTAINING A ZINC BINDING MOIETY | CURIS, INC. (US) | 2014-08-07 | — | — | US | disclosed |
| US-20140155606-A1 | QUINAZOLINE BASED EGFR INHIBITORS CONTAINING A ZINC BINDING MOIETY | CURIS, INC. (US) | 2014-06-05 | — | — | US | disclosed |
| US-8518910-B2 | Formulation of quinazoline based EGFR inhibitors containing a zinc binding moiety | CURIS, INC. (US) | 2013-08-27 | — | — | US | disclosed |
| US-8349856-B2 | Quinazoline based EGFR inhibitors | CURIS, INC. (US) | 2013-01-08 | — | — | US | disclosed |
| US-20120122881-A1 | FORMULATION OF QUINAZOLINE BASED EGFR INHIBITORS CONTAINING A ZINC BINDING MOIETY | CURIS, INC. | 2012-05-17 | — | — | US | disclosed |
| US-20110053963-A1 | TARTRATE SALTS OF QUINAZOLINE BASED EGFR INHIBITORS CONTAINING A ZINC BINDING MOIETY | CAI XIONG | 2011-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140228361-A1 | AMINOQUINAZOLINE DERIVATIVES AND THEIR SALTS AND METHODS OF USE | ABL1, PRKDC, JAK2 | EGFR 460/4885FBP1 4095/4885ERBB2 104/4885 |
| US-20140221403-A1 | QUINAZOLINE BASED EGFR INHIBITORS CONTAINING A ZINC BINDING MOIETY | EGFR, HDAC5, ERBB4 | EGFR 1/4885FBP1 1048/4885ERBB2 7/4885 |
| US-20140155606-A1 | QUINAZOLINE BASED EGFR INHIBITORS CONTAINING A ZINC BINDING MOIETY | EGFR, HDAC1, HDAC5 | EGFR 1/4885FBP1 950/4885ERBB2 5/4885 |
| US-20120122881-A1 | FORMULATION OF QUINAZOLINE BASED EGFR INHIBITORS CONTAINING A ZINC BINDING MOIETY | HDAC6, HDAC5, HDAC1 | EGFR 4/4885FBP1 1348/4885ERBB2 13/4885 |
| US-20150274678-A1 | QUINAZOLINE BASED EGFR INHIBITORS CONTAINING A ZINC BINDING MOIETY | EGFR, HDAC1, HDAC5 | EGFR 1/4885FBP1 950/4885ERBB2 5/4885 |
| US-20110053963-A1 | TARTRATE SALTS OF QUINAZOLINE BASED EGFR INHIBITORS CONTAINING A ZINC BINDING MOIETY | EGFR, HDAC1, HDAC5 | EGFR 1/4885FBP1 1182/4885ERBB2 6/4885 |
| US-20150284340-A1 | QUINAZOLINE BASED EGFR INHIBITORS CONTAINING A ZINC BINDING MOIETY | EGFR, ERBB4, HDAC5 | EGFR 1/4885FBP1 1022/4885ERBB2 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.